Learn about Our Clinical Trials


The Cancer Center at BIDMC is an important center of research into the safety and effectiveness of new cancer therapies. Your physician will help you evaluate whether participation in a clinical trial is appropriate for you.

If you have advanced cancer that has not responded to standard therapy, you may benefit from the BIDMC Cancer Center's Phase I Oncology program. For those who qualify, this program offers the option to participate in early stage early stage research studies investigating new anti-cancer agents.

Novel Therapies

Based on strong experimental and pre-clinical data, and cutting-edge science, these clinical trials research novel therapy and techniques that include:

  • Unique agents designed to improve the effects of standard chemotherapy
  • New cancer vaccines and other immunotherapies
  • Targeted agents to disable a specific cellular pathway
  • Innovative approaches to interfere with blood flow to tumors
  • New chemotherapeutic agents
  • State-of-the-art imaging techniques

Active and Enrolling Trials

The following Phase I clinical trials are now available through BIDMC. Please email PIO@bidmc.harvard.edu if you have questions about participating in clinical trials.

  • Safety, Pharmacokinetics, and Pharmacodynamics of Escalating Oral Doses of the Arginase Inhibitor INCB001158 (formerly known as CB- 1158) as a Single Agent and in Combination with Immune Checkpoint Ther-apy in Patients with Advanced/Metastatic Solid Tumors - Learn More.

  • Phase 1 Trial of ABT-888 and SCH727965 in Patients with Advanced Solid Tumors - Learn More.

  • A Phase 1/1b First-In-Human, Dose-Escalation Study to Evaluate the Safety, Tolerability, Pharmaco-kinetics, and Pharmacodynamics of IPI-549 Monotherapy and in Combination with Nivolumab in Sub-jects with Advanced Solid Tumors - Learn More.

  • A Platform Study Exploring the Safety, Tolerability, Effects on the Tumor Microenvironment, and Efficacy of Pembrolizumab (MK-3475) + INCB Combinations in Advanced Solid Tumors  - Learn More.

  • A Phase 1/2, Open-Label, Dose-Escalation, Safety and Tolerability Study of INCAGN01876 in Subjects With Advanced or Metastatic Solid Tumors  - Learn More.

  • A PHASE Ia/Ib OPEN-LABEL, DOSE-ESCALATION STUDY OF THE SAFETY AND PHARMACOKINETICS OF MTIG7192A AS A SINGLE AGENT AND IN COMBINATION WITH ATEZOLIZUMAB IN PATIENTS WITH LOCALLY ADVANCED OR METASTATIC TUMORS - Learn More.

  • A Phase 1b/2 Study of ARRY-382 in Combination with Pembrolizumab, a Programmed Cell Death Receptor 1 (PD-1) Antibody, for the Treatment of Patients with Advanced Solid Tumors - Learn More.

  • Phase I Study of the CDK4/6 Inhibitor Palbociclib (PD-0332991) in Combination with the PI3K/mTOR Inhibitor Gedatolisib (PF-05212384) for Patients with Advanced Squamous Cell Lung, Pancreatic, Head & Neck and Other Solid Tumors - Learn More.

  • Phase 1/2 Multicenter Trial of ICOS Agonist Monoclonal Antibody (mAb) JTX-2011 Alone and in Combination with Nivolumab, Ipilimumab, or Pembrolizumab in Adult Subjects with Advanced and/or Refractory Solid Tumor Malignancies - Learn More.

  • A Phase 1/2a Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of PLX8394 in Patients with Advanced, Unresectable Solid Tumors - Learn More.

  • Phase Ib study to test the safety and potential synergy of pembrolizumab (anti-PD-1) and AMG386 (angiopoietin-2 (Ang-2) in patients with advanced solid tumor - Learn More.

  • A Phase 1/1b Study of MGCD516 in Patients with Advanced Solid Tumor Malignancies - Learn More.

  • An Open-Label, Phase 2 Study of Neratinib in Patients with Solid Tumors with Somatic Human Epi-dermal Growth Factor Receptor (EGFR, HER2, HER3) Mutations or EGFR Gene Amplification - Learn More.

  • Phase 1/1b, Open-Label, Multicenter, Repeat-Dose, Dose-Selection Study of CPI-444 as Single Agent and in Combination with Atezolizumab in Patients with Selected Incurable Cancers  - Learn More.

  • Phase I, Multicenter, Open-Label, Clinical and Pharmacokinetics Study of PM01183 in Combination with Irinotecan in Pretreated Patients with Selected Advanced Solid Tumors - Learn More.

  • Non-Comparative, Open-Label, Multiple Cohort, Phase 1/2 Study of Nivolumab Monotherapy and Nivolumab Combination Therapy in Subjects with Virus-Positive and Virus-Negative Solid Tumors - Learn More.

  • A Multicenter, Open-Label Phase 1b/2 Trial of Lenvatinib (E7080) Plus Pembrolizumab in Subjects With Selected Solid Tumors  - Learn More.

  • A Clinical Trial of Pembrolizumab (MK-3475) Evaluating Predictive Biomarkers in Subjects with Ad-vanced Solid Tumors (KEYNOTE 158) - Learn More.

  • A Multicenter Phase II Clinical Trial of Lurbinectedin (PM01183) In Selected Advanced Solid Tu-mors - Learn More.

  • A Phase 1/2 Dose Escalation and Cohort Expansion Study of the Safety and Tolerability of Urelumab Administered in Combination with Nivolumab in Advanced /Metastatic Solid Tumors and B Cell Non-Hodgkins Lymphoma - Learn More.

  • Phase I Safety, Pharmacokinetic and Pharmacodynamic Study of PF-02341066, A C-MET/HGFR Selective Tyrosine Kinase Inhibitor, Administered Orally to Patients with Advanced Cancer. - Learn More.

  • A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Learn More.

  • A PHASE 1, DOSE-ESCALATION AND EXPANSION TRIAL OF PT2977, A HIF-2á INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS - Learn More.

  • A Phase 1/2 Study of the Safety, Pharmacokinetics, and Pharmacodynamics of the Glutaminase Inhibitor CB-839 in Combination with Nivolumab in Patients with Advanced/Metastatic Melanoma, Renal Cell Carcinoma and Non-Small Cell Lung Cancer - Learn More.

  • A PHASE 1, DOSE-ESCALATION AND EXPANSION TRIAL OF PT2977, A HIF-2á INHIBITOR, IN PATIENTS WITH ADVANCED SOLID TUMORS - Learn More.

Updated November 2018.